Lonza will host a webinar focused on CRISPR technology

| By | Lonza, Webinar
0
140

Today, CRISPR/Cas9 has emerged as the genome editing method of choice in research, medicine, and biotechnology. Compared to other gene editing technologies, it is simpler to re-engineer, easier to use, has broad versatility, and can target multiple sites.

One essential factor enabling to explore the full CRISPR potential is efficient delivery of its components into physiologically relevant cell types. Many renowned scientists are already using Lonza’s non-viral Nucleofector™ Technology for delivering CRISPR plasmids or RNPs efficiently into various cell types. This webinar will be focused on the best practices to achieve optimal delivery results.

Key learning objectives:

  • Understand the basic principle of CRISPR-based genome editing and its potential applications or modes of use
  • Learn how to achieve efficient delivery into hard-to-transfect cell lines, primary cells or stem cells
  • Get tips and tricks for using the Nucleofector™ Technology as a powerful non-viral delivery method

The webinar will take place on 29 May 2018. The presentation lasts 45 minutes and is followed by a live Q&A session. All registrants will receive access to the recorded webinar shortly after the webinar takes place. Registration and more details are available here.

SOURCE: lonza
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.